Navigation Links
Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
Date:8/7/2014

f its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the potential for the FDA to not approve NB32 even after meeting the prespecified threshold and resubmitting the NDA; the possibility that public disclosure of the results of the interim analysis of the Light Study would later be deemed to jeopardize the integrity of the Light Study potentially resulting in the requirement to conduct additional, costly studies; additional analysis of the interim results or new data from the continuing Light Study, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with the conclusion that the interim analysis was successful; the potential that the interim analysis may not be predictive of future results in the Light Study; the results from the interim analysis may not be sufficient to successfully respond to the questions raised regarding safety of NB32; the possibility that the CHMP requests additional or new data to be provided; the possibility that the CHMP determines to not approve NB32; the potential for early termination of Orexigen's North American collaboration agreement with Takeda; the possibility that Orexigen is unable to find a partner for NB32 in territories outside of North America, the final results of the Light Study may not support continued approval of NB32; the therapeutic and commercial value of NB32; the potential for additional costly clinical trials needed for Empatic; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these an
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
2. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
3. Orexigen Resubmits Contrave New Drug Application
4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
5. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
6. Orexigen Announces Successful Interim Analysis of Contrave Light Study
7. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
9. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
10. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
11. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... announces that a new market research report is ... Cardiac Defibrillators Industry http://www.reportlinker.com/p098394/Global-Cardiac-Defibrillators-Industry.html ... markets for Cardiac Defibrillators in Units and US$ ... analyzed by the following segments - Implantable/Internal Cardiac ...
... 24, 2011 Reportlinker.com announces that a new ... Global ECG Telemetry Devices Industry ... This report analyzes the worldwide markets for ... following Product Segments: Patient Digital Transmitters, Electrical Leads, ...
Cached Medicine Technology:Reportlinker Adds Global Cardiac Defibrillators Industry 2Reportlinker Adds Global ECG Telemetry Devices Industry 2
(Date:12/26/2014)... 2014 Yisrayl Hawkins, Pastor at The House ... in light of the Ferguson, Missouri unrest. Yisrayl starts his ... and explains why it has only increased. , He ... created. He says there is a very specific reason for ... there is a set of rules, or Laws that if ...
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... and colleagues from Northwestern University have found supplementation of ... to be effective in reducing the cancer cell growth. ... receptors (Human Epidermal Growth factor Receptor type 2), which ... aggressive and the activation of the receptors makes the ...
... name suggests is the excessive accumulation of fat in the ... may be a crucial one in explaining the association between ... concluded from the study that persons with fatty liver may ... ,The study was conducted among a group of 1,455 individuals ...
... have found effective results using Two screen and treat ... //,cervical cancer using low resource settings exclusively for developing ... the test and treat program was very much effective ... precancerous cervical lesions. ,Cervical Cancer: ,Cervical ...
... of a particular drug than the individual effect of both the ... where the avian bird flu is posing a serious threat across ... is a prescribed drug for seasonal flu, because it will be ... in Asia and reported in other areas mutates into a human ...
... the American Association for Cancer Research has leaned in a ... broccoli and garlic after several studies presented at the meeting ... being [resented with irrefutable news, experts are now of the ... be to change the way you eat, in other words ...
... is currently free of cases ... of importing vaccines to ... a government official.// ... up special central cell of ...
Cached Medicine News:Health News:Primrose oil reduces Breast cancer cell growth 2Health News:Persons With Fatty Liver More Prone For Hypertension 2Health News:Two screen test and treat screening for cervical cancer 2Health News:Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2
...
... provide you with an alternative method for ... proven design as Ad-Techs Spencer Probe Depth ... an introducing needle instead of a stylet. ... 3 to 6 platinum recording contacts, 5.0 ...
... Spencer Probe Depth Electrodes offers you superior ... main body structure which uses a special, ... become more flexible as it reaches body ... feature a small 1.0 mm diameter size. ...
... Miditron Junior II is ... analyser for standardised reflectance ... and software features allow ... performance and convenience to ...
Medicine Products: